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Cuts by Caspase-14 Control the 
Proteolysis of Filaggrin
Leopold Eckhart1 and Erwin Tschachler1,2
Although mutations in the filaggrin gene (FLG) have been shown to be associated 
with ichthyosis vulgaris and atopic dermatitis, the function and regulation of 
filaggrin remain incompletely understood. In this issue, Hoste et al. report that 
filaggrin is directly cleaved by caspase-14. Acting in concert with other proteases, 
caspase-14 controls the breakdown of filaggrin to free amino acids and amino 
acid derivatives that contribute to the hydration and UVB absorption capacity 
of the stratum corneum. These findings identify a new layer of complexity in the 
regulation of epidermal barrier function.
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Processing of filaggrin in the epidermis
Filaggrin became a focus of dermato-
logical research when mutations in its 
gene (FLG) were found to be associ-
ated with ichthyosis vulgaris and atopic 
dermatitis (Irvine and McLean, 2006). 
Because filaggrin is expressed only in 
keratinocytes, defects in the epidermal 
barrier are now considered likely to pre-
cede immune activation and allergies in 
patients with atopic dermatitis (Irvine and 
McLean, 2006). Although the mechanism 
of FLG-associated barrier defects has not 
yet been fully elucidated, recent stud-
ies have revealed multiple interactions 
between filaggrin and other proteins that 
are critical for its physiological function.
Like other members of the S100-fused-
type protein family, filaggrin is expressed 
as a precursor protein consisting of an 
N-terminal S100 domain and a series 
of filaggrin repeats. Proteolytic process-
ing yields filaggrin monomers that are 
important in the aggregation of interme-
diate filaments during cornification of 
keratinocytes (Steinert et al., 1981). In the 
stratum corneum, complete proteolysis of 
filaggrin leads to the release of free amino 
acids that function as components of the 
natural moisturizing factor (NMF) (Scott 
and Harding, 1986) (Figure 1). Moreover, 
filaggrin-derived histidine is converted 
to urocanic acid, which protects the 
underlying layers of the skin against UVB 
radiation (Barresi et al., 2011). In addition 
to proteolysis, protein phosphorylation, 
dephosphorylation, and deimination 
control the progressive conversion of 
profilaggrin to its amino acid constituents 
(Sandilands et al., 2009). The report by 
Hoste et al. (2011, this issue) uncovers a 
novel part of the complex processing of 
filaggrin and highlights the experimental 
challenges faced by investigators studying 
biochemical processes in the outermost 
layers of the skin.
caspase-14 is a filaggrin-processing enzyme
The cysteine protease caspase-14 was 
linked to the breakdown of filaggrin 
in 2007 by Declercq and colleagues, 
who generated and characterized a 
caspase-14 knockout mouse model 
(Denecker et al., 2007). They found that 
caspase-14 deficiency was associated 
with the accumulation of incompletely 
degraded filaggrin fragments within the 
stratum corneum, a decrease in stratum 
corneum hydration, increased trans-
epidermal water loss, and sensitivity 
to UVB photodamage. In an extension 
of this work, Hoste et al. (2011) now 
provide evidence for the molecular 
mechanisms underlying the phenotype 
of caspase-14 knockout mice. The 
investigators identify direct cleavage sites 
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of caspase-14 within filaggrin monomers 
in vitro and report that lack of caspase-14 
leads to a decrease in the concentration 
of filaggrin-derived components of the 
NMF and consequently to a decrease in 
the UVB photoprotectant urocanic acid 
in the stratum corneum (Hoste et al., 
2011).
Caspase-14 is coexpressed with 
filaggrin in terminally differentiated 
keratinocytes; it also undergoes proteo-
lytic maturation (Eckhart et al., 2000; 
Lippens et al., 2000; Figure 1). An as-
yet-unknown protease cleaves pro-
caspase-14 to generate a large and a 
small catalytic subunit that persist in the 
stratum corneum (Fischer et al., 2004; 
Hibino et al., 2010). The processing of 
caspase-14 is essential but not sufficient 
for catalytic activation (Mikolajczyk et 
al., 2004). In vitro high concentrations of 
kosmotropic (i.e., structure-stabilizing) 
salts are required for caspase-14 to be 
active (Mikolajczyk et al., 2004; Fischer 
et al., 2004; Hoste et al., 2011). As kos-
motropes exert their effects on proteins 
by competing for water molecules, the in 
vitro requirements of caspase-14 activity 
may be mimicked by the low water con-
tent known to exist close to the skin sur-
face. Indeed, filaggrin is degraded when 
the hydration level in the outer layers of 
the stratum corneum decreases (Scott and 
Harding, 1986). Further studies should 
define more precisely the microenviron-
ment that allows caspase-14 to cleave fil-
aggrin in the epidermis. It is tempting to 
speculate that a unique dependency on 
a distinct milieu allows caspase-14 to act 
as a sensor for environmental conditions 
that regulate the degradation of filaggrin.
Hoste et al. determined two sites 
of caspase-14-mediated cleavage of 
filaggrin in vitro, and they suggested 
the existence of other cleavage sites 
that could not be identified, largely for 
technical reasons. Both sites identi-
fied in this report conform to caspases’ 
strict requirement for an aspartate resi-
due on the amino-terminal side of the 
hydrolyzed peptide bond (Mikolajczyk 
et al., 2004). The substrate specific-
ity of caspases, including caspase-14, 
also depends on the three amino acid 
residues that precede the aspartate 
residue (Mikolajczyk et al., 2004). 
Intriguingly, filaggrin shows little evolu-
tionary conservation of its amino acid 
sequence, including the sequence of 
the caspase-14 cleavage sites identified 
by Hoste et al. (2011). Interspecies 
differences in the caspase-14 cleavage 
pattern of filaggrin and the existence of 
caspase-14 substrates other than filaggrin 
should be investigated in future studies.
caspase-14-dependent markers of 
filaggrin catabolism
The report of Hoste et al. (2011) shows 
that caspase-14 deficiency affects 
two molecular parameters of filaggrin 
catabolism: the pattern of filaggrin frag-
ments and the concentrations of NMF 
components in the stratum corneum. 
Previously, the NMF content of stra-
tum corneum has been suggested as a 
marker for FLG mutations (Kezic et al., 
2008). Hoste et al. (2011) now demon-
strate that, in addition to the mutation 
status of filaggrin, the efficiency of filag-
grin catabolism is a major determinant 
of NMF concentrations. Complementary 
to the decreased concentrations of NMF 
components, the absence of caspase-14 
is also associated with an increase in 
the abundance of filaggrin degrada-
tion intermediates (Hoste et al., 2011). 
It is conceivable that distinct patterns 
of filaggrin fragments correlate with 
different states of stratum corneum 
homeostasis or even with subsets of 
human diseases. Interestingly, the level 
of active caspase-14 has been reported 
to be reduced in patients with atopic 
dermatitis (Yamamoto et al., 2011). 
Unfortunately, the filaggrin fragmenta-
tion pattern was not determined in that 
study. The results of Hoste et al. (2011) 
suggest an unconventional migra-
tion behavior of filaggrin fragments in 
polyacrylamide gel electrophoresis. 
Therefore, the evaluation of alterna-
tive assays and the specific adaption of 
the analytical methods to the unique 
properties of filaggrin, including a high 
content of charged amino acid residues, 
may be required to define diagnostic 
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Figure 1. Proteolytic regulation of filaggrin and caspase-14. Filaggrin and caspase-14 are expressed 
as proproteins that undergo proteolytic maturation in the stratum granulosum. The subunits of 
caspase-14 (red and orange) require further structural changes, possibly induced by dimerization, to 
become catalytically active. Filaggrin monomers (blue) are cut at multiple sites by caspase-14 (red 
arrows) and other proteases (black arrowheads).
Clinical Implications
•  In addition to mutations in the filaggrin gene, defects in the activity of 
caspase-14 and possibly other proteases can lead to a decrease in the 
levels of stratum corneum natural moisturizing factor.
•  The identification of filaggrin processing intermediates in the stratum 
corneum may be used in the differential diagnosis of filaggrin-
associated skin barrier defects.
•  Modifying the microenvironment within the stratum corneum may 
become a strategy for treating disorders of filaggrin processing.
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It is important to note that Hoste et 
al. (2011) have not proposed that cas-
pase-14 is the only protease that cleaves 
filaggrin. Rather, their report shows that, 
in the absence of caspase-14, other 
enzymes can initiate proteolysis of filag-
grin. In addition, proteases such as cal-
pain 1 and bleomycin hydrolase (Kamata 
et al., 2009) are required to complete 
the degradation of filaggrin. Therefore, 
to understand the regulation of filaggrin 
degradation, it is necessary to determine 
the interplay of caspase-14 with these 
other proteases as well as the order in 
which the proteolytic cuts occur.
concluding remarks
New evidence demonstrates that not 
only mutations in the filaggrin gene but 
also alterations in filaggrin processing 
may result in skin barrier defects and 
that caspase-14 takes part in this pro-
cess. Hoste et al. (2011) provide a basis 
for improving strategies to diagnose 
filaggrin-associated skin disorders and to 
modulate caspase-14-dependent barrier 
function of the stratum corneum.
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Demonstration of Epitope Spreading 
in Bullous Pemphigoid: Results of a 
Prospective Multicenter Study
Takashi Hashimoto1,2, Daisuke Tsuruta1,2, Teruki Dainichi1,2, Takahiro 
Hamada1,2, Minao Furumura1,2 and Norito Ishii1,2
Di Zenzo and colleagues have undertaken a multicenter prospective study 
to clarify the epitope profile for IgG anti-BP180 and BP230 antibodies in 35 
patients with bullous pemphigoid (BP). Both intra- and intermolecular epitope 
spreading events were observed, in which epitopes shifted exclusively from 
extracellular to intracellular domains. The presence of IgG antibodies to the 
BP180 C-terminal domain and BP230, in addition to the BP180-NC16A domain, 
correlated with disease severity and activity, suggesting specific pathogenic rel-
evance for anti-BP230 antibodies. Epitope spreading was found in both T- and 
B-cell recognition. IgA anti LAD-1 antibodies are frequently found in patients 
with BP; these antibodies appear to follow the development of IgG antibodies 
to BP180 and BP230 by epitope spreading. These observations provide direction 
for future studies of the pathogenesis of and treatments for BP.
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epitope spreading plays an  
important role in the development  
of autoimmune diseases
Various autoimmune diseases develop 
and progress via epitope spreading (ES). 
In ES, inflammation induced by auto-
immunity to an initial epitope damages 
target tissue, which subsequently induc-
es antibodies to secondary epitopes on 
the same or different antigens (Chan 
et al., 1998). Intra- or intermolecular 
ES is not simply an epiphenomenon, 
because it is important for the develop-
ment of each disease.
